NCT04567251: Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

NCT04567251
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have no imaging evidence of disease progression within 4 months of enrollment
Exclusions: 
https://ClinicalTrials.gov/show/NCT04567251

Comments are closed.

Up ↑